• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma.

作者信息

Paulsson Johan O, Olander Anton, Haglund Felix, Zedenius Jan, Juhlin C Christofer

机构信息

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, CCK, SE-171 76, Stockholm, Sweden.

Department of Pathology and Cytology, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.

出版信息

Endocr Pathol. 2018 Dec;29(4):380-383. doi: 10.1007/s12022-018-9551-6.

DOI:10.1007/s12022-018-9551-6
PMID:30306386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6223712/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93d1/6223712/8604149ed084/12022_2018_9551_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93d1/6223712/8604149ed084/12022_2018_9551_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93d1/6223712/8604149ed084/12022_2018_9551_Fig1_HTML.jpg

相似文献

1
TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma.端粒酶逆转录酶免疫组化在滤泡性甲状腺癌中对端粒酶逆转录酶启动子突变和基因表达的预测价值不佳。
Endocr Pathol. 2018 Dec;29(4):380-383. doi: 10.1007/s12022-018-9551-6.
2
TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.TERT 启动子突变在转移性滤泡状甲状腺癌中的空间异质性：对临床检查的影响。
Endocr Pathol. 2019 Sep;30(3):246-248. doi: 10.1007/s12022-019-09580-7.
3
The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.滤泡性甲状腺细胞来源癌中与年龄和端粒缩短相关的TERT启动子突变
Oncogene. 2014 Oct 16;33(42):4978-84. doi: 10.1038/onc.2013.446. Epub 2013 Oct 21.
4
TERT Promoter Mutated Follicular Thyroid Carcinomas Exhibit a Distinct microRNA Expressional Profile with Potential Implications for Tumor Progression.端粒酶逆转录酶（TERT）启动子突变的滤泡性甲状腺癌表现出独特的微小RNA表达谱，对肿瘤进展可能具有潜在影响。
Endocr Pathol. 2021 Dec;32(4):513-516. doi: 10.1007/s12022-021-09695-w. Epub 2021 Oct 21.
5
A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!甲状腺滤泡性肿瘤中端粒酶相关异常作为诊断和预后标志物的临床概述：TERT预警！
Scand J Surg. 2020 Sep;109(3):187-192. doi: 10.1177/1457496919850434. Epub 2019 May 26.
6
5hmC Immunohistochemistry: A Predictor of Promoter Mutational Status in Follicular Thyroid Carcinoma?5hmC 免疫组化：滤泡状甲状腺癌启动子突变状态的预测指标？
J Histochem Cytochem. 2023 Aug;71(8):451-458. doi: 10.1369/00221554231190437. Epub 2023 Jul 24.
7
TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.甲状腺癌中的端粒酶逆转录酶（TERT）启动子突变：来自中东人群的报告。
Endocr Relat Cancer. 2015 Dec;22(6):901-8. doi: 10.1530/ERC-15-0396. Epub 2015 Sep 9.
8
TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine.TERT 启动子突变筛查作为预测滤泡性甲状腺肿瘤恶性行为的工具——来自临床常规的三个例子。
Virchows Arch. 2018 Nov;473(5):639-643. doi: 10.1007/s00428-018-2386-1. Epub 2018 Jun 2.
9
TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.TERT 启动子突变作为早期遗传事件，激活滤泡状甲状腺腺瘤（FTA）和非典型 FTA 中的端粒酶。
Cancer. 2014 Oct 1;120(19):2965-79. doi: 10.1002/cncr.28800. Epub 2014 Jun 4.
10
Effect of single-nucleotide polymorphism in TERT promoter on follicular thyroid tumor development.TERT 启动子中单核苷酸多态性对滤泡甲状腺肿瘤发生的影响。
Pathol Int. 2020 Apr;70(4):210-216. doi: 10.1111/pin.12893. Epub 2020 Jan 15.

引用本文的文献

1
TERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survival.端粒酶逆转录酶基因扩增作为甲状腺乳头状癌的风险分层标志物，与肿瘤复发和生存显著相关。
Endocr Pathol. 2025 Apr 24;36(1):15. doi: 10.1007/s12022-025-09853-4.
2
TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases.亚厘米级甲状腺乳头状癌及同步性淋巴结转移灶的端粒酶逆转录酶（TERT）RNAscope分析
Thyroid Res. 2024 Apr 15;17(1):8. doi: 10.1186/s13044-024-00195-7.
3
5hmC Immunohistochemistry: A Predictor of Promoter Mutational Status in Follicular Thyroid Carcinoma?

本文引用的文献

1
aberrancies: a screening tool for malignancy in follicular thyroid tumours.异常：滤泡性甲状腺肿瘤恶性肿瘤的筛查工具。
Endocr Relat Cancer. 2018 Jul;25(7):723-733. doi: 10.1530/ERC-18-0050. Epub 2018 Apr 24.
2
MicroRNA Regulation of Telomerase Reverse Transcriptase (TERT): Micro Machines Pull Strings of Papier-Mâché Puppets.微小 RNA 对端粒酶逆转录酶（TERT）的调控：微观机器拉动纸浆木偶的线。
Int J Mol Sci. 2018 Apr 1;19(4):1051. doi: 10.3390/ijms19041051.
3
Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma.
5hmC 免疫组化：滤泡状甲状腺癌启动子突变状态的预测指标？
J Histochem Cytochem. 2023 Aug;71(8):451-458. doi: 10.1369/00221554231190437. Epub 2023 Jul 24.
4
Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool.使用 RNAscope® 评估 TERT mRNA 表达：一种有潜力的组织病理学诊断和预后工具。
Pathol Res Pract. 2022 May;233:153892. doi: 10.1016/j.prp.2022.153892. Epub 2022 Apr 16.
5
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
6
Immunohistochemical and mutational status of telomerase reverse transcriptase in conjunctival squamous cell carcinoma.结膜鳞状细胞癌中端粒酶逆转录酶的免疫组织化学和突变状态。
Indian J Ophthalmol. 2022 Mar;70(3):971-975. doi: 10.4103/ijo.IJO_1342_21.
7
Nuclear-specific accumulation of () mRNA in promoter mutated follicular thyroid tumours visualised by in situ hybridisation: a possible clinical screening tool?通过原位杂交观察到启动子突变的滤泡性甲状腺肿瘤中（）mRNA的核特异性积累：一种可能的临床筛查工具？
J Clin Pathol. 2021 May 19;75(10):658-62. doi: 10.1136/jclinpath-2021-207631.
8
Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.甲状腺癌中端粒酶逆转录酶（TERT）的调控：综述。
Front Endocrinol (Lausanne). 2020 Jul 31;11:485. doi: 10.3389/fendo.2020.00485. eCollection 2020.
9
Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant promoter methylation, but not hot-spot mutations.小肠神经内分泌肿瘤中端粒酶的激活与启动子异常甲基化有关，但与热点突变无关。
Epigenetics. 2019 Dec;14(12):1224-1233. doi: 10.1080/15592294.2019.1634987. Epub 2019 Jul 19.
10
TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.TERT 启动子突变在转移性滤泡状甲状腺癌中的空间异质性：对临床检查的影响。
Endocr Pathol. 2019 Sep;30(3):246-248. doi: 10.1007/s12022-019-09580-7.
非透明细胞型和透明细胞型肝细胞癌中端粒酶的启动子突变及细胞分布
Oncotarget. 2017 Apr 18;8(16):26288-26297. doi: 10.18632/oncotarget.15458.
4
Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.分化型甲状腺癌中的端粒酶：启动子突变、表达及定位
Mol Cell Endocrinol. 2015 Jan 5;399:288-95. doi: 10.1016/j.mce.2014.10.019. Epub 2014 Oct 27.
5
Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression.具有自发转移进展的人横纹肌肉瘤细胞系的分子特征
Br J Cancer. 2000 Mar;82(6):1239-45. doi: 10.1054/bjoc.1999.1069.